PROK Company Profile and Key Details
ProKidney Corp.
PROK Stock Price Chart
Stock Price Today
ProKidney Corp. (PROK) stock surged +7.83%, trading at $1.79 on NASDAQ, up from the previous close of $1.66. The stock opened at $1.69, fluctuating between $1.64 and $1.82 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Company Information
| Employees | 163 |
| Beta | 1.3 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
ProKidney Corp. (NASDAQ: PROK) stock price is $1.79 in the last trading session. During the trading session, PROK stock reached the peak price of $1.82 while $1.64 was the lowest point it dropped to. The percentage change in PROK stock occurred in the recent session was 7.83% while the dollar amount for the price change in PROK stock was $0.13.
The NASDAQ listed PROK is part of Biotechnology industry that operates in the broader Healthcare sector. ProKidney Corp. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Mr. Timothy Lutz
Senior Vice President of Manufacturing
Dr. Libbie P. McKenzie M.D.
Chief Medical Officer
Ms. Mary Weger
Chief People Officer
Dr. Timothy A. Bertram D.V.M., Ph.D.
Founder, Chief Executive Officer & Director
Ms. Ashley H. Johns
Senior Vice President of Clinical Operations
Dr. Joseph M. Stavas M.D.
Senior Vice President of Clinical Devel.
Dr. Darin J. Weber Ph.D.
Chief Reg. Off, SVice President and Head of Global Reg. Affairs, Quality Mgmt, Biometrics & Market Access
Dr. Kerry Cooper M.D.
Senior Vice President of Medical Affairs
Dr. Deepak Jain Ph.D.
Chief Operating Officer
Mr. James Coulston CPA
Chief Financial Officer
Mr. James Coulston C.P.A.
Chief Financial Officer
Mr. Todd C. Girolamo Esq., J.D., M.B.A.
Chief Legal Officer & Corporation Sec.
Dr. Joseph M. Stavas M.D., M.P.H.
Senior Vice President and Head of Global Clinical Devel. & Interventional Procedures
Dr. Bruce Culleton M.D.
Executive Vice President of Clinical Devel. & Commercialization
Dr. Glenn Schulman M.P.H., Pharm. D., Pharm.D.
Vice President of Investor Relations & Corporation Communications
PROK's closing price is 40.68% higher than its 52-week low of $1.18 where as its distance from 52-week high of $4.44 is -62.61%.
Number of PROK employees currently stands at 163.
Official Website of PROK is: https://www.prokidney.com
PROK could be contacted at phone 336 999 7028 and can also be accessed through its website. PROK operates from 2000 Frontis Plaza Blvd., Winston-Salem, NC 27103, United States.
PROK stock volume for the day was 426.81K shares. The average number of PROK shares traded daily for last 3 months was 475.09K.
The market value of PROK currently stands at $522.16M with its latest stock price at $1.79 and 291.71M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com